Lineage Cell Therapeutics Q2 EPS Lowered by HC Wainwright

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Investment analysts at HC Wainwright cut their Q2 2025 EPS estimates for shares of Lineage Cell Therapeutics in a research report issued on Wednesday, May 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.02) per share for the quarter, down from their prior estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q3 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.07) EPS.

Several other equities research analysts have also recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. B. Riley dropped their target price on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $4.20.

Lineage Cell Therapeutics Stock Down 1.6%

Lineage Cell Therapeutics stock opened at $0.46 on Friday. The company has a market capitalization of $102.05 million, a PE ratio of -3.86 and a beta of 1.21. The firm has a fifty day simple moving average of $0.46 and a two-hundred day simple moving average of $0.63. Lineage Cell Therapeutics has a twelve month low of $0.37 and a twelve month high of $1.15.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in shares of Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after buying an additional 18,053 shares in the last quarter. HighTower Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after buying an additional 19,100 shares in the last quarter. Barclays PLC lifted its holdings in shares of Lineage Cell Therapeutics by 10.8% in the fourth quarter. Barclays PLC now owns 234,069 shares of the company’s stock worth $118,000 after buying an additional 22,769 shares in the last quarter. Fort Sheridan Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after buying an additional 23,000 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Lineage Cell Therapeutics by 33.0% in the fourth quarter. Wells Fargo & Company MN now owns 94,894 shares of the company’s stock worth $48,000 after buying an additional 23,527 shares in the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.